Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder - PubMed (original) (raw)
Clinical Trial
Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder
R J Steingard et al. J Child Adolesc Psychopharmacol. 1997 Spring.
Abstract
The intolerance of children with autistic disorder to changes in their routine or environment is well known, typically presenting with acute symptoms of anxiety, panic, irritability, or agitation. In a clinical sample of children (6-12 years old) with autistic disorder and transition-induced behavioral deterioration, 8 of 9 patients showed a clinically significant improvement in response to sertraline treatment. Only one child was taking concurrent psychotropic medication. Therapeutic doses were surprisingly low in all cases (25-50 mg daily), with a clinical response appearing generally in 2-8 weeks. Adverse effects were minimal (one child developed stomachaches), except for apparent sertraline-induced behavioral worsening in 2 children when their doses were raised to 75 mg daily. In 3 children, an initial satisfactory clinical response appeared to diminish after 3-7 months of treatment, despite steady or increased doses. In 6 patients, the beneficial effects persisted throughout the several-month follow-up period. Only four of the children's families were identified as having mood and/or anxiety disorders. This open-label study suggests that short-term sertraline treatment may reduce the behavioral reactions seen in association with situational transitions or environmental changes in children with autistic disorder, though the beneficial effect may be only temporary in some children. Our experience suggests that small doses of sertraline may be effective and that some children may require divided doses of sertraline during the day. Controlled studies are needed to determine the efficacy, safety, and pharmacokinetics of sertraline in treating this "need for sameness," both in short-term and long-term studies of children with autistic disorder.
Similar articles
- Sertraline response in adults with mental retardation and autistic disorder.
Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Hellings JA, et al. J Clin Psychiatry. 1996 Aug;57(8):333-6. J Clin Psychiatry. 1996. PMID: 8778118 Clinical Trial. - Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.
McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. McDougle CJ, et al. J Clin Psychopharmacol. 1998 Feb;18(1):62-6. doi: 10.1097/00004714-199802000-00010. J Clin Psychopharmacol. 1998. PMID: 9472844 Clinical Trial. - A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. Posey DJ, et al. J Child Adolesc Psychopharmacol. 2001 Fall;11(3):267-77. doi: 10.1089/10445460152595586. J Child Adolesc Psychopharmacol. 2001. PMID: 11642476 Clinical Trial. - Sertraline-induced behavioral activation during the treatment of an adolescent with major depression.
Guilé JM. Guilé JM. J Child Adolesc Psychopharmacol. 1996 Winter;6(4):281-5. doi: 10.1089/cap.1996.6.281. J Child Adolesc Psychopharmacol. 1996. PMID: 9231321 Review. - Methodologies and outcomes from the sertraline multicenter flexible-dose trials.
Rapaport MH, Wolkow RM, Clary CM. Rapaport MH, et al. Psychopharmacol Bull. 1998;34(2):183-9. Psychopharmacol Bull. 1998. PMID: 9640998 Review.
Cited by
- A Critical Review of the Psychomotor Agitation Treatment in Youth.
Tripodi B, Matarese I, Carbone MG. Tripodi B, et al. Life (Basel). 2023 Jan 20;13(2):293. doi: 10.3390/life13020293. Life (Basel). 2023. PMID: 36836652 Free PMC article. Review. - Treatment of comorbid anxiety and autism spectrum disorders.
Nadeau J, Sulkowski ML, Ung D, Wood JJ, Lewin AB, Murphy TK, May JE, Storch EA. Nadeau J, et al. Neuropsychiatry (London). 2011 Dec;1(6):567-578. doi: 10.2217/npy.11.62. Neuropsychiatry (London). 2011. PMID: 24174992 Free PMC article. - Pharmacotherapy for Fragile X Syndrome: Progress to Date.
Davenport MH, Schaefer TL, Friedmann KJ, Fitzpatrick SE, Erickson CA. Davenport MH, et al. Drugs. 2016 Mar;76(4):431-45. doi: 10.1007/s40265-016-0542-y. Drugs. 2016. PMID: 26858239 Review. - Emerging pharmacologic treatment options for fragile X syndrome.
Schaefer TL, Davenport MH, Erickson CA. Schaefer TL, et al. Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. eCollection 2015. Appl Clin Genet. 2015. PMID: 25897255 Free PMC article. Review. - Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.
Martin A, Koenig K, Anderson GM, Scahill L. Martin A, et al. J Autism Dev Disord. 2003 Feb;33(1):77-85. doi: 10.1023/a:1022234605695. J Autism Dev Disord. 2003. PMID: 12708582 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical